(this["webpackJsonpakqa-ui-test"]=this["webpackJsonpakqa-ui-test"]||[]).push([[8],{48:function(e,s,t){},59:function(e,s,t){"use strict";t.r(s);var a=t(2),i=t(1),c=t.p+"static/media/shika-awesome-goal.1f28d82c.mkv",r=t(28),l=t.n(r),n=t(3),o=t.n(n),A=(t(48),t(0));s.default=function(){var e=Object(i.useState)(!1),s=Object(a.a)(e,2),t=s[0],r=s[1],n=function(){console.log("play"),r(!t)};return Object(A.jsx)("div",{className:"main-video__overall-container",children:Object(A.jsxs)("div",{className:"main-video__page-wrapper",children:[Object(A.jsx)(o.a,{right:!0,children:Object(A.jsxs)("div",{className:"main-video__content-wrapper",children:[Object(A.jsxs)("p",{className:"main-video__main-text",children:[" ","Adtralza\xae neutralizes IL-13, a key driver of Atopic Dermatitis signs and symptoms."," "]}),Object(A.jsxs)("p",{className:"main-video__secondary-text",children:[" ","By specifically targeting the IL-13 cytokine, Adtralza\xae inhibits the interaction with type II receptors and prevents IL-13-induced inflammatory responses in the skin(1,2). ",Object(A.jsx)("br",{}),Object(A.jsx)("br",{})," Adtralza\xae selectively modulates the dysregulated immune system by(1): ",Object(A.jsx)("br",{})," ",Object(A.jsx)("br",{})," \u2014 Reducing markers of skin inflammation"," ",Object(A.jsx)("br",{})," \u2014 Improving markers of skin barrier integrity ",Object(A.jsx)("br",{})," \u2014 Reducing epidermal thickness"]})]})}),Object(A.jsx)(o.a,{left:!0,children:Object(A.jsxs)("div",{className:"main-video__video-wrapper",children:[Object(A.jsx)(l.a,{url:c,className:"main-video__video",playing:t,controls:!!t,onPlay:function(){return!t&&n()},onPause:function(){return t&&n()}}),!t&&Object(A.jsx)("img",{src:"data:image/png;base64,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",alt:"play-circle",className:"main-video__play-pause",onClick:n})]})})]})})}}}]);
//# sourceMappingURL=8.87ddd060.chunk.js.map